Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (141-150 of 198) with videos related to

Pageof 20
Sort By:
The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
Modern Rheumatology|November 7, 2024
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Arthritis Research & Therapy|October 22, 2014
An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3Jane Zochling, Felicity Newell, Jac C Charlesworth, et al.
Rheumatology (Oxford, England)|October 16, 2012
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Nicole Goh, Tamera Corte, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Rheumatology and Therapy|December 5, 2020
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)Ana-Maria Orbai, Jordi Gratacós, Anthony Turkiewicz, et al.
Rheumatology and Therapy|January 4, 2023
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Annals of the Rheumatic Diseases|February 2, 2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Pageof 20

Showing results (141-150 of 198) with videos related to

Sort By:
Pageof 20
The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
Modern Rheumatology|November 7, 2024
Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Arthritis Research & Therapy|October 22, 2014
An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3Jane Zochling, Felicity Newell, Jac C Charlesworth, et al.
Rheumatology (Oxford, England)|October 16, 2012
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung diseaseOwen A Moore, Nicole Goh, Tamera Corte, et al.
RMD Open|October 31, 2020
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programmeStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Rheumatology and Therapy|December 5, 2020
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)Ana-Maria Orbai, Jordi Gratacós, Anthony Turkiewicz, et al.
Rheumatology and Therapy|January 4, 2023
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
Arthritis Research & Therapy|January 19, 2015
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisYanjie Hao, Vivek Thakkar, Wendy Stevens, et al.
Annals of the Rheumatic Diseases|February 2, 2017
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsStanley B Cohen, Yoshiya Tanaka, Xavier Mariette, et al.
Pageof 20